Saxagliptin (709031-78-7) is a clinically useful DPPIV inhibitor for the treatment of diabetes.1 ?Human DPP-IV Ki = 0.6 nM.2
Saxagliptin is a potent and selective reversible inhibitor of dipeptidyl peptidase-4, which is being developed for the treatment of type 2 diabetes. It is absorbed rapidly after oral administration and has a pharmacokinetic profile compatible with once daily dosing.
Tahrani et al. (2009) Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus; Adv. Ther. 26 249
Augeri et al. (2005) Discovery and Preclinical Profile of Saxagliptin (BMS-477118): A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes; J. Med. Chem. 48 5025